Radiotherapy provider Nucletron has received Food and Drug Administration 510(k) clearance for its Swift real-time intraoperative treatment-planning system for high-dose brachytherapy prostate cancer treatment. Swift, which is based on live ultrasound imaging, allows clinicians to generate a 3-D volume, create a treatment plan, place needles, evaluate and optimize needle placement and treatment dosages, and begin patient treatment within one hour, according to the Veenendaal, Netherlands-based firm.
Clinicians can use Swift to create a conformal treatment plan during the implantation procedure, allowing needle adjustment while in the operating room. This opens up the possibility of a first treatment being given while the patient is still in the operating room, Nucletron said.
By AuntMinnie.com staff writers
August 21, 2003
Related Reading
Siemens and Nucletron to partner, August 7, 2003
Nucletron books 1,000th Simulix sale, April 10, 2003
Nucletron adds Merry X-Ray, December 10, 2002
Nucletron product gets FDA 510(k) clearance, November 20, 2002
Nucletron, Novation enter three-year accord, October 17, 2002
Copyright © 2003 AuntMinnie.com
